Comparison · NCT02807272-deaths
CMML vs MDS/MPS: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. CMML vs MDS/MPS: deaths from any cause. Trial comparisons, record NCT02807272-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02807272-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.459 | 0.31 | 0.616 | wilson | |
| Risk in group 2 | 0.143 | 0.0257 | 0.513 | wilson | |
| Risk difference, group 1 minus group 2 | 0.317 | -0.0826 | 0.512 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 3.22 | 0.507 | 20.4 | log | |
| Odds ratio, group 1 over group 2 | 5.1 | 0.557 | 46.7 | log | |
| Number needed to harm, for one more death from any cause on CMML than on MDS/MPS | 3.16 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | CMML | Participants with CMML were grouped by KRAS/NRAS mutational status (wild type \[WT\], mutation \[Mut\], missing) and given tipifarnib 1200mg twice daily (BID) for 7 days in alternating weeks (Days 1-7, 15-21) in 28-day cycles. | 17 | 37 | EG000 |
| Group 2 | MDS/MPS | Participants with MDS/MPN were stratified by ratio of expression (high or low) between CXCR4 and CXCR2 (CXCR4/2 ratio) receptors to receive tipifarnib at a dose of 400 mg, orally, BID on Day 1 through 21 of each 28-day treatment cycle. | 1 | 7 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- Up to approximately 3 years
Source ClinicalTrials.gov
Trial
- Title
- Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia
- NCT number
- NCT02807272
- Phases
- PHASE2
- Conditions
- Leukemia, Myelomonocytic, Chronic
- Interventions
- Tipifarnib
- Lead sponsor
- Kura Oncology, Inc.
- Results first posted
- 2024-07-17
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02807272?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02807272-deaths